These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30285276)

  • 1. Dabigatran as a Treatment Option for Heparin-Induced Thrombocytopenia.
    Nasiripour S; Saif M; Farasatinasab M; Emami S; Amouzegar A; Basi A; Mokhtari M
    J Clin Pharmacol; 2019 Jan; 59(1):107-111. PubMed ID: 30285276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Zarei B; Moghtadaei M; Nasiripour S; Ansarinejad N; Zarei M
    J Clin Pharmacol; 2020 Oct; 60(10):1362-1366. PubMed ID: 32519800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia.
    Davis KA; Davis DO
    Eur J Haematol; 2017 Oct; 99(4):332-335. PubMed ID: 28672052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review.
    Wang Y; Zhang K; Yin L; Fu G; Liu Z
    Ann Vasc Surg; 2022 Mar; 80():392.e1-392.e7. PubMed ID: 34656708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heparin-induced thrombocytopenia. New therapeutical options].
    Seculini Patiño CE; Tabares AH
    Medicina (B Aires); 2016; 76(4):230-4. PubMed ID: 27576282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Balouchzehi S; Moghaddam OM; Ansarinejad N; Mohammadi M; Nasiripour S
    J Clin Pharmacol; 2022 Nov; 62(11):1379-1384. PubMed ID: 35656855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis - case report and systematic review of dabigatran use.
    Di Pilla M; Barco S; Sacco C; Barosi G; Lodigiani C
    Vasa; 2021 Feb; 50(2):151-156. PubMed ID: 32597318
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia.
    Snodgrass MN; Shields J; Rai H
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.
    Tran PN; Tran MH
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):201-209. PubMed ID: 28301915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
    Frame JN; Rice L; Bartholomew JR; Whelton A
    Clin Ther; 2010 Apr; 32(4):626-36. PubMed ID: 20435232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group.
    Joseph J; Rabbolini D; Enjeti AK; Favaloro E; Kopp MC; McRae S; Pasalic L; Tan CW; Ward CM; Chong BH
    Med J Aust; 2019 Jun; 210(11):509-516. PubMed ID: 31155728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study.
    Linkins LA; Warkentin TE; Pai M; Shivakumar S; Manji RA; Wells PS; Wu C; Nazi I; Crowther MA
    J Thromb Haemost; 2016 Jun; 14(6):1206-10. PubMed ID: 27061271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing.
    Dykes KC; Johnson CA; Gong JZ; McKenzie SE; Husseinzadeh HD
    Clin Appl Thromb Hemost; 2021; 27():1076029621996473. PubMed ID: 33848189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.
    Padmanabhan A; Jones CG; Curtis BR; Bougie DW; Sullivan MJ; Peswani N; McFarland JG; Eastwood D; Wang D; Aster RH
    Chest; 2016 Sep; 150(3):506-15. PubMed ID: 26905366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial.
    Crowther M; Cook D; Guyatt G; Zytaruk N; McDonald E; Williamson D; Albert M; Dodek P; Finfer S; Vallance S; Heels-Ansdell D; McIntyre L; Mehta S; Lamontagne F; Muscedere J; Jacka M; Lesur O; Kutsiogiannis J; Friedrich J; Klinger JR; Qushmaq I; Burry L; Khwaja K; Sheppard JA; Warkentin TE; ; ;
    J Crit Care; 2014 Jun; 29(3):470.e7-15. PubMed ID: 24726205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.